Early-onset lamellar cataract
diseaseOn this page
Summary
Early-onset lamellar cataract (MONDO:0018611) is a disease with 12 cohort genes.
At a glance
- Cohort genes: 12
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | early-onset lamellar cataract |
| Mondo ID | MONDO:0018611 |
| Orphanet | 441452 |
| UMLS | C5681191 |
| MedGen | 1843303 |
| GARD | 0013155 |
| Is cancer (heuristic) | no |
Data availability: 11 GenCC gene-disease records.
Disease family
Classification path: human disease › disease by body system or component › disorder of orbital region › eye disorder › lens disorder › cataract › early-onset non-syndromic cataract › early-onset partial cataract › early-onset zonular cataract › cataract 16 multiple types › early-onset lamellar cataract
Related subtypes (1): early-onset posterior polar cataract
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 100 · Orphanet: 43 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| BFSP2 | Definitive | Autosomal dominant | cataract 12 multiple types | 9 |
| CRYAA | Definitive | Autosomal recessive | cataract 9 multiple types | 8 |
| CRYBA1 | Definitive | Autosomal dominant | cataract 10 multiple types | 7 |
| CRYBA4 | Definitive | Autosomal dominant | cataract 23 | 6 |
| CRYGC | Definitive | Autosomal dominant | cataract 2, multiple types | 7 |
| CRYGD | Definitive | Autosomal dominant | cataract 4 multiple types | 9 |
| CRYGS | Definitive | Autosomal dominant | cataract 20 multiple types | 5 |
| HSF4 | Definitive | Autosomal dominant | cataract 5 multiple types | 7 |
| MIP | Definitive | Autosomal dominant | cataract 15 multiple types | 10 |
| TNPO1 | Definitive | Autosomal dominant | cataract 15 multiple types | 11 |
| CRYAB | Strong | Autosomal dominant | cataract 16 multiple types | 16 |
| CRYGB | Supportive | Autosomal dominant | early-onset lamellar cataract | 5 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| BFSP2 | Orphanet:441452 | Early-onset lamellar cataract |
| BFSP2 | Orphanet:98984 | Pulverulent cataract |
| BFSP2 | Orphanet:98985 | Early-onset sutural cataract |
| CRYAA | Orphanet:1377 | Cataract-microcornea syndrome |
| CRYAA | Orphanet:441452 | Early-onset lamellar cataract |
| CRYAA | Orphanet:98988 | Early-onset anterior polar cataract |
| CRYAA | Orphanet:98991 | Early-onset nuclear cataract |
| CRYAA | Orphanet:98994 | Total early-onset cataract |
| CRYAB | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| CRYAB | Orphanet:280553 | Fatal infantile hypertonic myofibrillar myopathy |
| CRYAB | Orphanet:399058 | Alpha-B crystallin-related late-onset myopathy |
| CRYAB | Orphanet:441452 | Early-onset lamellar cataract |
| CRYAB | Orphanet:98991 | Early-onset nuclear cataract |
| CRYAB | Orphanet:98993 | Early-onset posterior polar cataract |
| CRYBA1 | Orphanet:441452 | Early-onset lamellar cataract |
| CRYBA1 | Orphanet:98985 | Early-onset sutural cataract |
| CRYBA1 | Orphanet:98991 | Early-onset nuclear cataract |
| CRYBA1 | Orphanet:98993 | Early-onset posterior polar cataract |
| CRYBA4 | Orphanet:1377 | Cataract-microcornea syndrome |
| CRYBA4 | Orphanet:441452 | Early-onset lamellar cataract |
| CRYGB | Orphanet:441452 | Early-onset lamellar cataract |
| CRYGB | Orphanet:98988 | Early-onset anterior polar cataract |
| CRYGB | Orphanet:98994 | Total early-onset cataract |
| CRYGC | Orphanet:1377 | Cataract-microcornea syndrome |
| CRYGC | Orphanet:441452 | Early-onset lamellar cataract |
| CRYGC | Orphanet:98984 | Pulverulent cataract |
| CRYGC | Orphanet:98991 | Early-onset nuclear cataract |
| CRYGD | Orphanet:1377 | Cataract-microcornea syndrome |
| CRYGD | Orphanet:441452 | Early-onset lamellar cataract |
| CRYGD | Orphanet:98984 | Pulverulent cataract |
| CRYGD | Orphanet:98989 | Cerulean cataract |
| CRYGD | Orphanet:98990 | Coralliform cataract |
| CRYGD | Orphanet:98991 | Early-onset nuclear cataract |
| CRYGS | Orphanet:441452 | Early-onset lamellar cataract |
| CRYGS | Orphanet:98985 | Early-onset sutural cataract |
| HSF4 | Orphanet:441452 | Early-onset lamellar cataract |
| HSF4 | Orphanet:98994 | Total early-onset cataract |
| MIP | Orphanet:441452 | Early-onset lamellar cataract |
| MIP | Orphanet:98985 | Early-onset sutural cataract |
| MIP | Orphanet:98989 | Cerulean cataract |
| MIP | Orphanet:98991 | Early-onset nuclear cataract |
| MIP | Orphanet:98993 | Early-onset posterior polar cataract |
| MIP | Orphanet:98994 | Total early-onset cataract |
Cohort genes → proteins
12 cohort genes, 12 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 12 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| BFSP2 | HGNC:1041 | ENSG00000170819 | Q13515 | Phakinin | gencc |
| CRYAA | HGNC:2388 | ENSG00000160202 | P02489 | Alpha-crystallin A chain | gencc |
| CRYAB | HGNC:2389 | ENSG00000109846 | P02511 | Alpha-crystallin B chain | gencc |
| CRYBA1 | HGNC:2394 | ENSG00000108255 | P05813 | Beta-crystallin A3 | gencc |
| CRYBA4 | HGNC:2396 | ENSG00000196431 | P53673 | Beta-crystallin A4 | gencc |
| CRYGB | HGNC:2409 | ENSG00000182187 | P07316 | Gamma-crystallin B | gencc |
| CRYGC | HGNC:2410 | ENSG00000163254 | P07315 | Gamma-crystallin C | gencc |
| CRYGD | HGNC:2411 | ENSG00000118231 | P07320 | Gamma-crystallin D | gencc |
| CRYGS | HGNC:2417 | ENSG00000213139 | P22914 | Gamma-crystallin S | gencc |
| HSF4 | HGNC:5227 | ENSG00000102878 | Q9ULV5 | Heat shock factor protein 4 | gencc |
| TNPO1 | HGNC:6401 | ENSG00000083312 | Q92973 | Transportin-1 | gencc |
| MIP | HGNC:7103 | ENSG00000135517 | P30301 | Lens fiber major intrinsic protein | gencc |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| BFSP2 | Phakinin | Required for the correct formation of lens intermediate filaments as part of a complex composed of BFSP1, BFSP2 and CRYAA. |
| CRYAA | Alpha-crystallin A chain | Contributes to the transparency and refractive index of the lens. |
| CRYAB | Alpha-crystallin B chain | May contribute to the transparency and refractive index of the lens. |
| CRYBA1 | Beta-crystallin A3 | Crystallins are the dominant structural components of the vertebrate eye lens. |
| CRYBA4 | Beta-crystallin A4 | Crystallins are the dominant structural components of the vertebrate eye lens. |
| CRYGB | Gamma-crystallin B | Crystallins are the dominant structural components of the vertebrate eye lens. |
| CRYGC | Gamma-crystallin C | Crystallins are the dominant structural components of the vertebrate eye lens. |
| CRYGD | Gamma-crystallin D | Crystallins are the dominant structural components of the vertebrate eye lens. |
| CRYGS | Gamma-crystallin S | Crystallins are the dominant structural components of the vertebrate eye lens. |
| HSF4 | Heat shock factor protein 4 | Heat-shock transcription factor that specifically binds heat shock promoter elements (HSE). |
| TNPO1 | Transportin-1 | Functions in nuclear protein import as nuclear transport receptor. |
| MIP | Lens fiber major intrinsic protein | Aquaporins form homotetrameric transmembrane channels, with each monomer independently mediating water transport across the plasma membrane along its osmotic gradient. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 12 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 12 | 1.8× | 9e-04 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| BFSP2 | Other/Unknown | no | Keratin_I, IF_rod_dom | |
| CRYAA | Other/Unknown | no | Alpha-crystallin/sHSP_animal, A-crystallin/Hsp20_dom, Alpha-crystallin_N | |
| CRYAB | Other/Unknown | no | Alpha-crystallin/sHSP_animal, A-crystallin/Hsp20_dom, Alpha-crystallin_N | |
| CRYBA1 | Other/Unknown | no | Beta/gamma_crystallin, G_crystallin-like, Beta/Gamma-Crystallin | |
| CRYBA4 | Other/Unknown | no | Beta/gamma_crystallin, G_crystallin-like, Beta/Gamma-Crystallin | |
| CRYGB | Other/Unknown | no | Beta/gamma_crystallin, G_crystallin-like, Beta/Gamma-Crystallin | |
| CRYGC | Other/Unknown | no | Beta/gamma_crystallin, G_crystallin-like, Beta/Gamma-Crystallin | |
| CRYGD | Other/Unknown | no | Beta/gamma_crystallin, G_crystallin-like, Beta/Gamma-Crystallin | |
| CRYGS | Other/Unknown | no | Beta/gamma_crystallin, G_crystallin-like, Beta/Gamma-Crystallin | |
| HSF4 | Other/Unknown | no | HSF_DNA-bd, WH-like_DNA-bd_sf, WH_DNA-bd_sf | |
| TNPO1 | Other/Unknown | no | Importin-beta_N, ARM-like, ARM-type_fold | |
| MIP | Other/Unknown | no | MIP, MIP_CS, Aquaporin-like |
Expression context
Cohort genes with no expression data: 0.
6 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 1 |
| broad (>20) | 11 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | 7 |
| primordial germ cell in gonad | 6 |
| lens of camera-type eye | 3 |
| right lobe of liver | 2 |
| cerebellar cortex | 2 |
| cerebellar hemisphere | 2 |
| adult mammalian kidney | 1 |
| liver | 1 |
| cardiac ventricle | 1 |
| left ventricle myocardium | 1 |
| middle frontal gyrus | 1 |
| frontal pole | 1 |
| skeletal muscle tissue of rectus abdominis | 1 |
| sperm | 1 |
| testis | 1 |
| ventricular zone | 1 |
| right hemisphere of cerebellum | 1 |
| caput epididymis | 1 |
| cauda epididymis | 1 |
| corpus epididymis | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| BFSP2 | 111 | tissue_specific | yes | lens of camera-type eye, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad |
| CRYAA | 42 | marker | adult mammalian kidney, right lobe of liver, liver | |
| CRYAB | 289 | ubiquitous | marker | middle frontal gyrus, left ventricle myocardium, cardiac ventricle |
| CRYBA1 | 138 | tissue_specific | yes | lens of camera-type eye, primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis |
| CRYBA4 | 72 | tissue_specific | marker | male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, frontal pole |
| CRYGB | 35 | tissue_specific | yes | male germ line stem cell (sensu Vertebrata) in testis, sperm, skeletal muscle tissue of rectus abdominis |
| CRYGC | 15 | tissue_specific | yes | male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, testis |
| CRYGD | 60 | tissue_specific | marker | male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, ventricular zone |
| CRYGS | 179 | tissue_specific | yes | lens of camera-type eye, cerebellar hemisphere, cerebellar cortex |
| HSF4 | 186 | tissue_specific | marker | right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex |
| TNPO1 | 295 | ubiquitous | marker | corpus epididymis, caput epididymis, cauda epididymis |
| MIP | 91 | tissue_specific | yes | male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, right lobe of liver |
Protein interactions among cohort
Intra-cohort edges: 33.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| CRYAB | 3,368 |
| TNPO1 | 3,147 |
| MIP | 2,496 |
| CRYGC | 2,111 |
| CRYAA | 1,464 |
| BFSP2 | 1,203 |
| HSF4 | 967 |
| CRYBA1 | 925 |
| CRYBA4 | 601 |
| CRYGS | 513 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| BFSP2 | CRYAA | string_interaction |
| BFSP2 | CRYBA1 | string_interaction |
| BFSP2 | CRYBA4 | string_interaction |
| BFSP2 | CRYGB | string_interaction |
| BFSP2 | CRYGC | string_interaction |
| BFSP2 | CRYGD | string_interaction |
| BFSP2 | CRYGS | string_interaction |
| BFSP2 | HSF4 | string_interaction |
| BFSP2 | MIP | string_interaction |
| CRYAA | CRYAB | biogrid_interaction, intact |
| CRYAA | CRYBA1 | biogrid_interaction, string_interaction |
| CRYAA | CRYBA4 | string_interaction |
| CRYAA | CRYGB | string_interaction |
| CRYAA | CRYGC | biogrid_interaction, intact, string_interaction |
| CRYAA | CRYGD | biogrid_interaction, string_interaction |
| CRYAA | CRYGS | string_interaction |
| CRYAA | HSF4 | string_interaction |
| CRYAB | CRYBA1 | string_interaction |
| CRYAB | CRYBA4 | string_interaction |
| CRYAB | CRYGB | string_interaction |
| CRYAB | CRYGC | biogrid_interaction, intact |
| CRYAB | CRYGD | biogrid_interaction, string_interaction |
| CRYAB | CRYGS | biogrid_interaction, intact, string_interaction |
| CRYBA1 | HSF4 | string_interaction |
| CRYBA4 | HSF4 | string_interaction |
| CRYBA4 | MIP | string_interaction |
| CRYGB | CRYGC | biogrid_interaction, intact |
| CRYGC | CRYGD | biogrid_interaction |
| CRYGD | HSF4 | string_interaction |
| CRYGD | MIP | string_interaction |
| CRYGS | HSF4 | string_interaction |
| CRYGS | MIP | string_interaction |
| HSF4 | MIP | string_interaction |
Structural data
PDB: 9 · AlphaFold-only: 3 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| CRYAB | P02511 | 21 |
| TNPO1 | Q92973 | 21 |
| CRYGD | P07320 | 16 |
| CRYGS | P22914 | 12 |
| CRYAA | P02489 | 5 |
| CRYGB | P07316 | 2 |
| HSF4 | Q9ULV5 | 2 |
| CRYBA4 | P53673 | 1 |
| CRYGC | P07315 | 1 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| MIP | P30301 | 91.08 |
| CRYBA1 | P05813 | 88.27 |
| BFSP2 | Q13515 | 78.15 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 10. Enrichment computed across 12 evidence-associated genes (4 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| HSF1-dependent transactivation | 2 | 158.6× | 6e-04 | CRYAB, CRYBA4 |
| Passive transport by Aquaporins | 1 | 219.6× | 0.015 | MIP |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 1 | 158.6× | 0.015 | TNPO1 |
| Attenuation phase | 1 | 102.0× | 0.015 | CRYBA4 |
| Postmitotic nuclear pore complex (NPC) reformation | 1 | 102.0× | 0.015 | TNPO1 |
| HSF1 activation | 1 | 95.2× | 0.015 | CRYBA4 |
| Aquaporin-mediated transport | 1 | 92.1× | 0.015 | MIP |
| Intraflagellar transport | 1 | 50.1× | 0.025 | TNPO1 |
| Regulation of HSF1-mediated heat shock response | 1 | 34.8× | 0.032 | CRYBA4 |
| Transport of small molecules | 1 | 6.3× | 0.150 | MIP |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 12 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| lens development in camera-type eye | 9 | 280.9× | 3e-20 | CRYAA, CRYAB, CRYBA1, CRYBA4, CRYGB, CRYGC, CRYGD, CRYGS (+1 more) |
| visual perception | 9 | 59.6× | 4e-14 | BFSP2, CRYAA, CRYBA1, CRYBA4, CRYGB, CRYGC, CRYGD, CRYGS (+1 more) |
| negative regulation of intracellular transport | 2 | 936.2× | 3e-05 | CRYAA, CRYAB |
| apoptotic process involved in morphogenesis | 2 | 468.1× | 9e-05 | CRYAA, CRYAB |
| lens fiber cell morphogenesis | 2 | 351.1× | 1e-04 | CRYAA, CRYGB |
| tubulin complex assembly | 2 | 280.9× | 2e-04 | CRYAA, CRYAB |
| lens fiber cell differentiation | 2 | 175.5× | 4e-04 | CRYGD, HSF4 |
| protein refolding | 2 | 104.0× | 0.001 | CRYAA, CRYAB |
| response to hydrogen peroxide | 2 | 78.0× | 0.002 | CRYAA, CRYAB |
| response to heat | 2 | 70.2× | 0.002 | CRYAA, CRYAB |
| microtubule polymerization or depolymerization | 1 | 1404.3× | 0.003 | CRYAB |
| response to UV-A | 1 | 351.1× | 0.013 | CRYAA |
| regulation of programmed cell death | 1 | 234.1× | 0.016 | CRYAB |
| gap junction-mediated intercellular transport | 1 | 234.1× | 0.016 | MIP |
| maintenance of lens transparency | 1 | 175.5× | 0.019 | MIP |
| lens fiber cell development | 1 | 175.5× | 0.019 | BFSP2 |
| positive regulation of anoikis | 1 | 156.0× | 0.020 | CRYBA1 |
| response to hypoxia | 2 | 16.0× | 0.020 | CRYAA, CRYAB |
| homotypic cell-cell adhesion | 1 | 140.4× | 0.020 | MIP |
| glutathione biosynthetic process | 1 | 127.7× | 0.021 | CRYAA |
| negative regulation of amyloid fibril formation | 1 | 108.0× | 0.024 | CRYAB |
| embryonic camera-type eye morphogenesis | 1 | 93.6× | 0.026 | CRYAA |
| water transport | 1 | 82.6× | 0.026 | MIP |
| microtubule-based process | 1 | 82.6× | 0.026 | CRYAA |
| negative regulation of reactive oxygen species metabolic process | 1 | 78.0× | 0.026 | CRYAB |
| negative regulation of gene expression | 2 | 11.5× | 0.026 | CRYAA, CRYAB |
| protein stabilization | 2 | 11.2× | 0.027 | CRYAA, CRYAB |
| stress-activated MAPK cascade | 1 | 58.5× | 0.033 | CRYAB |
| cellular response to gamma radiation | 1 | 50.1× | 0.037 | CRYAB |
| negative regulation of TOR signaling | 1 | 46.8× | 0.038 | CRYBA1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 12
Druggability breadth: 6 of 12 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| BFSP2 | 0 | 0 |
| CRYAA | 0 | 0 |
| CRYAB | 0 | 0 |
| CRYBA1 | 0 | 0 |
| CRYBA4 | 0 | 0 |
| CRYGB | 0 | 0 |
| CRYGC | 0 | 0 |
| CRYGD | 0 | 0 |
| CRYGS | 0 | 0 |
| HSF4 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| CRYAA | 25 | Binding:25 |
| CRYAB | 13 | Binding:13 |
| CRYGC | 9 | Binding:9 |
| CRYGD | 9 | Binding:9 |
| TNPO1 | 7 | Binding:7 |
| HSF4 | 1 | Binding:1 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 12; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 12 | BFSP2, CRYAA, CRYAB, CRYBA1, CRYBA4, CRYGB, CRYGC, CRYGD, CRYGS, HSF4 (+2 more) |
Undrugged target profiles
12 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| BFSP2 | 0 | — |
| CRYAA | 25 | — |
| CRYAB | 13 | — |
| CRYBA1 | 0 | — |
| CRYBA4 | 0 | — |
| CRYGB | 0 | — |
| CRYGC | 9 | — |
| CRYGD | 9 | — |
| CRYGS | 0 | — |
| HSF4 | 1 | — |
| TNPO1 | 7 | — |
| MIP | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.